Protocol Ledger

NCT05949801 · Phase III · COMPLETED

Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

Interventional Phase III clinical trial protocol NCT05949801 sponsored by Zensun Sci. & Tech. Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-13 Enrollment: 202 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05949801
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)202 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05949801
Protocol FieldVerified Registry Value
NCT IdentifierNCT05949801
Consolidated Lead SponsorZensun Sci. & Tech. Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment202 participants (ACTUAL)
Registered Start Date2023-04-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05949801
Hospital Research SiteLocationSite Profile
Beijing Friendship Hospital , Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI